Arixtra filed for acute treatment uses in Japan
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has made a regulatory submission in Japan for the approval of Arixtra (fondaparinux sodium) for the additional indications of treatment of acute pulmonary thromboembolism and acute deep vein thrombosis (DVT).